Skip to main content

Table 1 Demographic characteristics, disease history, duration on study and reasons for discontinuation

From: Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Patient # Race Disease history a Prior therapy Study drug treatment duration
(Days)
Reason for discontinuation
   SLE
(Months)
LN
(Months)
Prior renal flare MMF CTX   
2 African American 38 < 1 - - - 148 Leukocytoclastic vasculitis
8
3
Caucasian 46 38 + + - 85 Study termination
  African American < 1 < 1 - - - 29 H. influenzae pneumonia,
IgG < 3 g/l
5 African American 3 < 1 - - - 230 Study termination
13 African American 52 52 + + + 31 IgG < 3 g/lb
14 Asian 32 < 1 + + + 18 IgG < 3 g/l
  1. Patients' mean (SD) height and weight were 169.3 (9.7) cm and 83.3 (20.8) kg, respectively. Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and#14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). aDisease history: time between SLE/LN diagnosis and consent. All patients had Class IV renal disease. bPatient #13 diagnosed with severe Legionella pneumonia on Day 34, 1 day after study discontinuation. CTX, cyclophosphamide; IgG, immunoglobulin G; LN, lupus nephritis; MMF, mycophenolate mofetil; SLE, systemic lupus erythematosus.